Fibrosis is an important health problem and its pathogenetic principles are still largely unknown. It can develop either spontaneously or, more frequently, as a consequence of various underlying diseases. However, irrespective of the primary cause, fibrotic tissue is always infiltrated by mononuclear immune cells. In most instances the reason for the attraction of these cells to fibrotic tissue and their proliferation remains to be determined, however their cytokine profile shows clear-cut proinflammatory and profibrotic characteristics. In this review we discuss the innate and adaptive immune reactions associated with the development of fibrosis and the molecular basis of the profibrotic mechanisms taking place in systemic sclerosis (scleroderma), arteriosclerosis and peri-silicone mammary implant fibrosis. Fibrosis: a disease with an immune-mediated etiologyFibrosis, i.e. excessive extracellular matrix (ECM) formation with proliferation and activation of myofibroblasts, is a major global health problem, but its etiology, pathogenesis, diagnosis and therapy have yet to be addressed in detail in either basic or clinical research settings. In principle, fibrosis can occur as a consequence of many different pathologic conditions (Figure 1), the most important of which arise either spontaneously, from tissue damage, inflammatory disease, in response to foreign implants, or from tumors (see Table 1).Although the pathologic processes initiating and perpetuating these processes are rather diverse, from a biochemical and pathohistological view the end stage of the development of fibrosis seems to be very stereotypic. Thus, in all cases studied the early stages of fibrotic conditions are characterized by immunologic-inflammatory hallmarks, viz. a perivascular infiltration by mononuclear cells and the subsequent imbalance of anti-and profibrotic cytokine profiles. In most of these instances, the original antigenic stimuli triggering the lymphoid infiltration have not been identified. The emphasis of this review is placed on the general role of innate and adaptive immunity, and the respective cytokines involved in the development of fibrosis.

The authors' results indicate that silicone implants trigger a specific, antigen-driven local immune response through activated TH1/TH17 cells, suggesting that ensuing fibrosis is promoted by the production of profibrotic cytokines as a consequence of faltering function of local T regulatory cells.

Background: As one of the few modifiable risk factors, the importance of dietary patterns for both disease prevention and treatment outcome in pediatric oncology has gained increasing popularity. Malnutrition is associated with lower survival rates, tolerance to treatment, and quality of life. Yet, especially in children with malignancies, nutritional deterioration is common, and pediatric cancer patients often present with inadequate intake of micro- and macronutrients alike. Despite the reported widespread use of dietary supplements, few empirical data provide a basis for clinical recommendations, and evidence for their efficacy is inconsistent. Current literature lacks a systematic approach as to how and which supplements should be recommended for specific patients, types of cancer, or during specific treatments. The aim of this review is to highlight the role of the most frequently used nutrients in pediatric malignant diseases and to give a practical guide based on current scientific evidence. Methods: A comprehensive literature search was conducted on PubMed through April 2023 to select meta-analyses, systematic reviews, observational studies, and individual randomized controlled trials (RCTs) of macro- and micronutrient supplementation in pediatric oncology. The search strategy included the following medical subject headings (MeSH) and keywords: “childhood cancer”, “pediatric oncology”, “nutritional status”, “dietary supplements”, “vitamins”, “micronutrients”, “calcium”, “magnesium”, “vitamin D”, “zinc” “glutamine”, “selen”, and “omega-3 fatty acids”. The reference lists of all relevant articles were screened to include potentially pertinent studies. Results: The present review provides a comprehensive and updated overview of the latest evidence about the role of nutrition and diet in pediatric oncology, also focusing on different nutritional interventions available for the management of the disease. We summarize evidence about the importance of adequate nutrition in childhood cancer and the role of several micronutrients and critically interpret the findings. Possible effects and benefits of supplementation during chemotherapy are discussed, as are strategies for primary and secondary prevention. Conclusions: We here describe the obvious benefits of dietary supplementation for childhood cancer. Further large-scale clinical trials are required to verify the impacts of deficiencies and the possible benefits of supplementation and optimal dosages. (337 words).